Funder: The Association for Frontotemporal Degeneration
Due Dates: November 9, 2018 (Letter of Intent) | February 15, 2019 (Invited Full Proposal) | June 1, 2026 (Full Proposal)
Funding Amounts: Up to $2,500,000 over 1–3 years per project; milestone-based payments; co-funding encouraged.
Summary: Supports early-stage clinical trials to advance effective treatments for frontotemporal degeneration, emphasizing strong scientific rationale, biomarkers, and innovative trial designs.